President Donald Trump is correct that prescription drugs cost too much. Families are struggling, and no one should have to choose between paying for their child’s inhaler or rent. But a new partnership between Trump and Pfizer to sell drugs directly to consumers won’t cure the disease, but rather embrace the government favoritism that made healthcare unaffordable in the first place.

Washington, D.C., keeps trying to fix healthcare by controlling it, and that’s the real problem. Each new regulation, tariff, or political deal promises to make medicine more affordable, yet costs keep rising while innovation slows. The cure for high drug prices isn’t more government control. It’s competition, the one thing Washington, D.C., can’t seem to stop meddling with.

TRUMP ANNOUNCES DEAL WITH ASTRAZENECA TO LOWER DRUG COSTS

TrumpRX, created by this Pfizer deal, will provide a government-directed new direct-to-consumer plan touted as a bold step toward transparency and savings. In reality, it’s another government-blessed arrangement that rewards one company while punishing competitors. Because Pfizer is already building U.S. plants, it’s exempt from the administration’s 100% tariff on branded drug imports. Smaller biotech firms and future innovators,........

© Washington Examiner